GT Biopharma Ownership | Who Owns GT Biopharma?

GT Biopharma Ownership Summary

GT Biopharma is owned by 6.97% institutional investors, 5.81% insiders, and 87.22% retail investors. Vanguard capital management is the largest institutional shareholder, holding 1.24% of GTBP shares. Vanguard Institutional Extnd Mkt Idx Tr is the top mutual fund, with 0.85% of its assets in GT Biopharma shares.

GTBP Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	GT Biopharma	6.97%	5.81%	87.22%
Sector	Healthcare Stocks	50.44%	12.38%	37.18%
Industry	Biotech Stocks	48.97%	12.07%	38.96%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Vanguard capital management	376.40K	1.24%	$184.44K
Geode capital management	266.79K	0.88%	$130.65K
Vanguard fiduciary trust	225.94K	0.75%	$110.71K
Hrt financial lp	107.14K	0.35%	$52.00K
Everhart financial group	100.00K	0.33%	$48.97K
Srs capital advisors	93.63K	0.31%	$45.85K
Caitlin john	16.50K	0.30%	$6.73K
Opal wealth advisors	81.81K	0.27%	$40.06K
Northern trust	75.46K	0.25%	$36.95K
49 wealth management	64.00K	0.21%	$31.34K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Kitching partners	50.00K	0.02%	$24.48K
Opal wealth advisors	81.81K	0.01%	$40.06K
49 wealth management	64.00K	0.01%	$31.34K
Caitlin john	16.50K	0.00%	$6.73K
Everhart financial group	100.00K	0.00%	$48.97K
Seacrest wealth management	50.10K	0.00%	$24.53K
Private wealth management group	20.00K	0.00%	$9.79K
Coston, mcisaac & partners	17.09K	0.00%	$8.00K
Tempus wealth planning	15.00K	0.00%	$7.35K
Am investment strategies	15.00K	0.00%	$7.00K

Top Buyers

Holder	Shares	% Assets	Change
Hrt financial lp	107.14K	0.00%	107.14K
Everhart financial group	100.00K	0.00%	100.00K
Opal wealth advisors	81.81K	0.01%	81.81K
Northern trust	75.46K	-	75.46K
49 wealth management	64.00K	0.01%	64.00K

Top Sellers

Holder	Shares	% Assets	Change
Drw securities	-	-	-142.38K
Vanguard capital management	376.40K	-	-75.48K
Citadel advisors	-	-	-66.17K
Scientech research	-	-	-54.74K
Ubs group	2.00	-	-45.97K

New Positions

Holder	Shares	% Assets	Change	Value
Everhart financial group	100.00K	0.00%	100.00K	$48.97K
Opal wealth advisors	81.81K	0.01%	81.81K	$40.06K
Northern trust	75.46K	-	75.46K	$36.95K
49 wealth management	64.00K	0.01%	64.00K	$31.34K
Cetera investment advisers	55.94K	-	55.94K	$27.39K

Sold Out

Holder	Change
Sbi securities	-1.00
Front row advisors	-1.00
Jpmorgan chase	-1.00
Blue bell private wealth management	-10.00
Ghp investment advisors	-33.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2026	57	46.15%	2,112,169	30.94%	6	24.58%	31	47.62%	8	60.00%
Mar 31, 2026	20	-47.37%	941,791	94.98%	17	11.37%	10	-60.00%	1	-87.50%
Dec 31, 2025	29	38.10%	284,740	-23.91%	7	3.96%	20	185.71%	5	25.00%
Sep 30, 2025	20	-	374,216	92.24%	13	19.59%	7	-36.36%	4	33.33%
Jun 30, 2025	21	5.00%	189,926	90.52%	8	44.82%	11	120.00%	3	-40.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Institutional Extnd Mkt Idx Tr	376.40K	0.85%	-
Fidelity Extended Market Index	168.34K	0.38%	-10.64K
Spartan Extended Market Index Pool E	4.50K	0.20%	4.26K
Fidelity Series Total Market Index	61.94K	0.14%	37.65K
Northern Trust Extended Eq Market Idx	45.27K	0.10%	44.88K
NT Ext Equity Mkt Index Fund - Lending	45.27K	0.10%	44.88K
Dimensional US Core Equity USD Acc	2.20K	0.10%	-
Spartan Extended Market Index Pool F	33.53K	0.08%	258.00
NT Ext Equity Mkt Index Fund - NL	30.12K	0.07%	29.51K
BlackRock Extended Equity Market K	1.16K	0.05%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Apr 11, 2023	Breen Michael Martin	Executive Chairman/Interim CEO	Buy	$25.00K
Apr 06, 2023	Ohri Manu	CFO & Secretary	Buy	$25.00K
Dec 22, 2020	Wendel Bruce	-	Buy	$12.19K
Nov 16, 2020	Wendel Bruce	-	Buy	$10.26K
Dec 22, 2020	Wendel Bruce	-	Buy	$3.85K

Insider Transactions Trends

Date	Buy	Sell
2023 Q2	2	-
2023 Q1	-	-
2022 Q3	-	-
2022 Q2	-	-
2022 Q1	-	-

GTBP Ownership FAQ

Who Owns GT Biopharma?

GT Biopharma shareholders are primarily institutional investors at 6.97%, followed by 5.81% insiders and 87.22% retail investors. The average institutional ownership in GT Biopharma's industry, Biotech Stocks , is 48.97%, which GT Biopharma falls below.

Who owns the most shares of GT Biopharma?

GT Biopharma’s largest shareholders are Vanguard capital management (376.4K shares, 1.24%), Geode capital management (266.79K shares, 0.88%), and Vanguard fiduciary trust (225.94K shares, 0.75%). Together, they hold 2.87% of GT Biopharma’s total shares outstanding.

Does Blackrock own GT Biopharma?

BlackRock is not among the top 10 institutional shareholders of GT Biopharma.

Who is GT Biopharma’s biggest shareholder by percentage of total assets invested?

Kitching partners is GT Biopharma’s biggest shareholder by percentage of total assets invested, with 0.02% of its assets in 50K GT Biopharma shares, valued at 24.48K$.

Who is the top mutual fund holder of GT Biopharma shares?

Vanguard Institutional Extnd Mkt Idx Tr is the top mutual fund holder of GT Biopharma shares, with 0.85% of its total shares outstanding invested in 376.4K GT Biopharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools